Market Overview - The Shanghai Composite Index closed at 4085.77 points, up 0.05%, with a trading volume of 11,974 billion yuan [1] - The Shenzhen Component Index closed at 14,030.56 points, up 0.06%, with a trading volume of 16,567.97 billion yuan [1] - The ChiNext Index closed at 3,329.69 points, up 0.31%, with a trading volume of 7,632.51 billion yuan [1] - The STAR Market 50 Index closed at 1,443.39 points, up 0.99%, with a trading volume of 871 million yuan [1] - The total trading volume of both markets was 28,541.97 billion yuan, an increase of 475.91 billion yuan compared to the previous trading day [1] Sector Performance - Strong sectors included coal, electronics, telecommunications, power equipment, pharmaceutical biology, construction decoration, steel, and machinery equipment [2] - Weak sectors included oil and petrochemicals, securities, beauty care, education, banking, and precious metals [2] - The top-performing stocks were concentrated in electronics, machinery equipment, chemicals, telecommunications, and pharmaceutical biology [2] Individual Stock Performance - 2,078 stocks rose, while 3,003 stocks fell, with 93 stocks remaining flat and 9 stocks suspended [2] - Among the stocks with the most consecutive daily limits, Victory Energy led with 14 consecutive limit-ups [4] - 110 stocks saw net inflows exceeding 100 million yuan, with Aerospace Development receiving the highest net inflow of 1.933 billion yuan [8][9] Fund Flow Analysis - The net outflow of main funds in the Shanghai and Shenzhen markets was 47.198 billion yuan, with the ChiNext seeing a net outflow of 17.043 billion yuan [5] - Seven sectors experienced net inflows, with the telecommunications sector seeing the highest inflow of 2.814 billion yuan [5] - The defense industry had the largest net outflow of 8.7 billion yuan, followed by computer, automotive, electronics, and power equipment sectors [5] Institutional Activity - Institutions had a net buy of 2.12 billion yuan, with the highest net buy in Sanbo Brain Science at approximately 266.27 million yuan [14][15] - The most sold stock by institutions was Goldwind Technology, with a net sell of approximately 406.44 million yuan [14][15]

证券之星消息，1月7日医疗服务板块较上一交易日上涨1.7%，益诺思领涨。当日上证指数报收于 4085.77，上涨0.05%。深证成指报收于14030.56，上涨0.06%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688710 | 益诺思 | 55.31 | 20.00% | 5.97万 | | 3.17亿 | | 688222 | 成都先导 | 30.44 | 13.67% | 44.49万 | | 13.43亿 | | 301293 | 三博脑科 | 93.82 | 10.45% | 74.53万 | | 68.62亿 | | 002173 | 创新医疗 | 28.63 | 9.99% | 10.16万 | | 2.91亿 | | 688621 | 阳光诺和 | 72.10 | 7.77% | 6.88万 | | 4.95 乙 | | 603127 | 昭衍新药 | 41.30 | 7.41% | 36.68万 | | 14.97亿 | | ...

钛媒体App 1月7日消息，创新医疗公告称，公司股票于2026年1月5日至7日连续三个交易日内收盘价格 涨幅偏离值累计超过20%，属于股票交易异常波动情形。经核实，公司前期披露的信息不存在需要更 正、补充之处，近期公司生产经营情况及内外部经营环境未发生重大变化，公司、控股股东及实际控制 人不存在应披露而未披露的重大事项。公司提醒广大投资者理性投资，注意投资风险。（公司公告） ...

创新医疗1月7日发布公告，公司股票于2026年1月5日至7日连续三个交易日内收盘价格涨幅偏离值累计 超过20%，属于股票交易异常波动情形。经核实，公司前期披露的信息不存在需要更正、补充之处，近 期公司生产经营情况及内外部经营环境未发生重大变化，公司、控股股东及实际控制人不存在应披露而 未披露的重大事项。公司提醒广大投资者理性投资，注意投资风险。 ...

证券代码：002173 证券简称：创新医疗 公告编号：2026-001 创新医疗管理股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 创新医疗管理股份有限公司（以下简称"公司"）股票（证券简称：创新医 疗，股票代码：002173）于2026年1月5日、6日、7日连续三个交易日内日收盘价 格涨幅偏离值累计超过20%，根据《深圳证券交易所交易规则》的有关规定，公 司股票属于交易异常波动的情形。 二、公司关注、核实情况的说明 针对公司股票交易异常波动情况，公司对控股股东及实际控制人、公司董事 及高级管理人员就相关问题进行了核实，现将有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 1、公司经过自查不存在违反信息公平披露的情形。 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息。 3、近期公司生产经营情况及内外部经营环境未发生重大变化。 4、公司、控股股东及实际控制人不存在应披露而未披露的重大事项，也不 存在未披露的处于筹划阶段的重大事项。 ...

2026年A股开门红，脑机接口相关概念股均迎来暴涨。 自1月5日开始，三博脑科（301293）、翔宇医疗、美好医疗（301363）、伟思医疗、诚益通（300430） 等股票连续多个交易日出现20%涨停，冠昊生物（300238）、塞力医疗（603716）、创新医疗 （002173）、南京熊猫（600775）、岩山科技（002195）等也都连续10%涨停。截至1月7日记者发稿， 脑机接口板块依然涨停不断。 多重利好消息传来 消息面上，埃隆.马斯克近日表示，旗下脑机接口公司Neuralink将于2026年开始大规模生产脑机接口设 备，并将同步推进流程高度精简、几乎完全自动化的外科手术方案。这一表态更是引发脑机接口相关概 念股热度快速攀升。有消息称，量产后，脑机单台植入手术的成本将从百万美元降至10万美元以内，全 自动化落地后有望进一步下探至5万美元区间，为日后脑机接口设备的大规模商业化埋下伏笔。 国内政策层面，2025年7月，工业和信息化部、国家发展改革委、教育部、国家卫生健康委、国务院国 资委、中国科学院、国家药监局七部门联合印发《关于推动脑机接口产业创新发展的实施意见》（以下 简称《意见》），首次系统性地明确了 ...

Core Insights - Strong Brain Technology, a brain-computer interface "unicorn," recently completed approximately 2 billion yuan in financing, making it the second-largest financing in the global brain-computer interface sector, following Neuralink [1] - The financing round attracted prestigious investors, including IDG Capital, Huaden International founded by Intel CEO Chen Lifeng, and several technology and education companies [1] - The brain-computer interface sector has seen a surge in secondary capital, with the sector's stocks rising over 20% in the last three trading days [1] Company Overview - Founded in 2015, Strong Brain Technology is recognized alongside innovative companies like DeepSeek and Yuzhu Technology as part of the "Hangzhou Six Little Dragons" [1] - Unlike Neuralink, Strong Brain Technology focuses on the development of non-invasive brain-computer interface technology [1] - The company's products span rehabilitation medicine, smart health, and intelligent education, with FDA and CE certifications obtained [1] Product and Market Potential - The core product, "Super Sensor," can detect weak brain electrical signals without invasive procedures, converting them into neural signals to control external devices [1] - The product currently assists individuals with physical disabilities in performing activities like running and complex sports [2] - Strong Brain Technology aims to help 1 million disabled individuals regain mobility and assist 10 million patients with Alzheimer's, autism, and insomnia over the next 5-10 years [2] Financial and Investment Highlights - Strong Brain Technology has attracted significant investment since its inception, completing multiple funding rounds, including a $400 million Series A in 2019 and subsequent rounds totaling $30 million and $20 million [2] - As of 2024, the company's valuation stands at 8.5 billion yuan according to the Hurun Global Unicorn List [2] - The company is reportedly preparing for an IPO, potentially in Hong Kong or mainland China, after completing over $100 million in pre-IPO financing by 2025 [2] Industry Trends - According to research from Open Source Securities, brain-computer interface technology is expected to commercialize by 2026, expanding from medical necessities into AI applications and robotics [2] - The commercialization path for non-invasive products is clear, indicating significant revenue potential in the future [2]

Core Viewpoint - The company Aihuilong (688575.SH) is entering the brain-computer interface (BCI) sector through a strategic cooperation agreement with Shenzhen Brain Machine Starlink Technology Co., Ltd, aiming to enhance diagnostic technology for central nervous system diseases and expand market reach [1][4]. Group 1: Strategic Cooperation - Aihuilong signed a strategic cooperation framework agreement with Brain Machine Starlink to integrate BCI technology with clinical and market resources [1]. - The company committed to leveraging its influence to enhance Brain Machine Starlink's financing and governance capabilities [2]. - The cooperation aims to develop BCI-related products and promote market expansion, although it has raised questions regarding the feasibility and synergy of the collaboration [2][12]. Group 2: Financial Performance - Aihuilong's revenue for the first three quarters of 2025 was 1.287 billion yuan, a year-on-year decline of 7.69%, with net profit dropping 72.36% to 60.42 million yuan [4]. - The company's stock price fell by 8.83% over the past year, with its market capitalization dropping to around 9 billion yuan [4]. - Despite the announcement of the BCI cooperation, the company's financial outlook remains uncertain, with no immediate impact on performance expected [10]. Group 3: Market Reaction - Following the announcement, Aihuilong's stock price initially rose by 3% but later experienced a decline [11]. - The Shanghai Stock Exchange issued an inquiry regarding the cooperation, questioning potential insider trading and requiring additional disclosures about the partnership [3][12]. - The BCI sector has seen a surge in interest, with related stocks experiencing significant gains, influenced by announcements from other companies in the field [10].

记者丨雷若馨 编辑丨孙超逸 2022年的冬季残奥会上，失去左臂及右臂大部分的运动员贾红光，佩戴着智能仿生手，通过非侵入式脑机接口技术识别大脑意图，顺利完成火炬交接和传 递。 2025年的冬天，马斯克宣布，脑机接口公司"神经连接（Neuralink）"将启动大规模脑机接口输出，并计划转向近乎全自动化手术，引爆全球医疗行业热度。 新年伊始，A股脑机接口概念板块接连两个交易日掀涨停潮，超50亿元资金流入。Wind数据显示，最近三个交易日，脑机接口指数累计涨幅超过14%。 1月7日早盘，脑机接口概念延续强势，创新医疗、南京熊猫双双3连板。 | 名称 | 现价 | 涨跌幅 ▼ | 换手率 | 市智率 | 年初至今 | | --- | --- | --- | --- | --- | --- | | 美好医疗 | 41.49 | 19.81% | 20.53% | 75.1 | 72.52% | | 创新医疗 | 28.63 | 9.99% | 1.65% | -206 | 33.10% | | 开立医疗 | 28.56 | 3.48% | 2.34% | 185 | 8.10% | | 航天长峰 | 26.15 | 2. ...

Core Viewpoint - The article highlights the rapid growth and investment potential in the brain-computer interface (BCI) sector, driven by technological advancements and significant market interest, particularly following announcements from Neuralink regarding large-scale production and automation of BCI devices [1][4][14]. Market Performance - The A-share BCI concept sector experienced a surge, with over 5 billion yuan flowing into the market, and the BCI index showing a cumulative increase of over 14% in the first three trading days of the year [1][8][11]. - Notable stocks in the BCI sector include Meihao Medical, which saw a 19.81% increase, and Innovation Medical, which rose by 9.99% [2]. Industry Overview - BCI technology connects the brain with external devices for information exchange, categorized into three types: invasive, semi-invasive, and non-invasive, each with varying levels of signal quality and risk [4]. - The healthcare sector is identified as the primary application area for BCI technology, accounting for 56% of its applications, with projections estimating the global BCI medical application market to reach $40 billion by 2030 and $145 billion by 2040 [4][6]. Policy and Development - The Chinese government has included BCI in its "14th Five-Year Plan," with goals for core technology breakthroughs by 2027 and positioning the industry among the world's leaders by 2030 [5][6]. - In 2025, several companies, including Boryeong and Ladder Medical, completed significant implantation trials, marking China's entry into clinical trials for invasive BCI after the U.S. [6]. Company Developments - Companies like Beiyikang and Aipeng Medical are actively involved in BCI, with Aipeng focusing on non-invasive technologies and partnerships for rehabilitation systems [10][12]. - Other firms, such as Xiangyu Medical and Xinwei Medical, are developing various BCI products and are expected to see rapid revenue growth in the coming years [10][12]. Investment Landscape - The BCI sector has attracted significant investment, with nearly 100 financing events in the past five years totaling over 10 billion yuan, and a notable 30% year-on-year increase in financing activities in 2025 [14]. - Analysts suggest that the BCI industry is on the verge of commercial growth, supported by policy and technological advancements, while also cautioning about the challenges of clinical validation and high costs [14][15].